Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CSPC Pharmaceutical Group's Debt-to-EBITDA or its related term are showing as below:
STU:CVG'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.01 Med: 0.07 Max: 0.35
Current: 0.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of CSPC Pharmaceutical Group was 0.35. The lowest was 0.01. And the median was 0.07.
STU:CVG's Debt-to-EBITDA is ranked better than 90.66% of 685
companies
in the Drug Manufacturers industry
Industry Median: 1.58
vs STU:CVG: 0.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CSPC Pharmaceutical Group Debt-to-EBITDA Related Terms
CSPC Pharmaceutical Group Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CVG vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, CSPC Pharmaceutical Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSPC Pharmaceutical Group Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CSPC Pharmaceutical Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CSPC Pharmaceutical Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
CSPC Pharmaceutical Group (STU:CVG) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CSPC Pharmaceutical Group. Over the past decade, CSPC Pharmaceutical Group's Debt-to-EBITDA has ranged from 0.01 to 0.35. According to the industry distribution chart, CSPC Pharmaceutical Group ranks #64 out of 685 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is CSPC Pharmaceutical Group's Debt-to-EBITDA too high?
CSPC Pharmaceutical Group's current Debt-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.35. Based on the distribution chart, CSPC Pharmaceutical Group ranks #64 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CSPC Pharmaceutical Group has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CSPC Pharmaceutical Group's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, CSPC Pharmaceutical Group ranks #64 out of 685 companies for Debt-to-EBITDA. This places CSPC Pharmaceutical Group in the top 9% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.58. Historically, CSPC Pharmaceutical Group's own Debt-to-EBITDA has ranged from 0.01 to 0.35 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.58, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CSPC Pharmaceutical Group. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSPC Pharmaceutical Group's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSPC Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group (STU:CVG) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.74, compared to a current price of €1.00 — trading 34.6% above its estimated fair value. The current Debt-to-EBITDA is 0.00. CSPC Pharmaceutical Group's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CSPC Pharmaceutical Group (STU:CVG), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSPC Pharmaceutical Group (STU:CVG) Overvalued in 2026?
Based on GuruFocus' analysis, CSPC Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.00 is trading 34.6% above its estimated GF Value™ of €0.74.
GuruFocus considers CSPC Pharmaceutical Group to be Significantly Overvalued.
Key valuation signals for STU:CVG:
Debt-to-EBITDA: 0.00
GF Value™: €0.74 vs. price of €1.00 (34.6% above fair value)
No single metric tells the full story. See the STU:CVG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
50GF Score
Get the complete analysis for STU:CVG
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CVG has been successfully added to your 
